Deming Tan

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)

Qin Ning, Meifang Han, Yongtao Sun et al. · Journal of Hepatology · 2014 · 279 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

Jinlin Hou, You‐Kuan Yin, Dao-zhen Xu et al. · Hepatology · 2007 · 163 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues

Rong Fan, Jian Sun, Quan Yuan et al. · Gut · 2015 · 125 citations · Full text

Pharmacy, Immunology, Pharmacology +17

Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries

Jin-Lin Hou, Wei Zhao, Changhyeong Lee et al. · Clinical Gastroenterology and Hepatology · 2019 · 112 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Long non-coding RNA MALAT1 promotes angiogenesis and immunosuppressive properties of HCC cells by sponging miR-140

Zhouhua Hou, Xuwen Xu, Xiaoyu Fu et al. · American Journal of Physiology-Cell Physiology · 2019 · 109 citations

Medicine, Cancer Biology, Oncology +17